ABEO (abeonatherapeutics.com) Multiplikator Forward P/S

Lambang korporat lan logo Abeona Therapeutics Inc. (ABEO)

Abeona Therapeutics (ABEO) is preparing to launch a unique gene therapy to combat epidermolysis bullosa. However, global instability and sanctions are complicating the transportation of biomaterials, thereby limiting expansion. In-house capacities and research variability in the field of ophthalmology mitigate development risks. The trend of the company's future P/S ratio clearly demonstrates market expectations, with the current value equal to 3.50.

Abeona Therapeutics, Inc. - Multiplikator Forward P/S ABEO (periode 04.07.2022 - 15.11.2026)

Ringkesan rincian data analitis Abeona Therapeutics Inc. (ABEO)

Analisis fundamental perusahaan:Abeona Therapeutics ABEO
Produk asli abeonatherapeutics.com

Diversified biocomponent supply chains minimize operational risks for Abeona Therapeutics (ABEO), establishing a foundation for predictable revenue growth. When analyzing the forward P/S metric, an investor assesses the ratio of the business's market value to expected sales; a decline in this ratio on the chart may indicate that the asset is undervalued, while an increase signals inflated market expectations regarding future cash flows.

Pesaing Abeona Therapeutics

Rasio rega marang prakiraan pendapatan Vertex VRTX|ALNY (Alnylam Inc.) - Rega mangsa ngarep marang pendapatan|Insmed Incorporated - Multiplikator Forward P/S|Rega forward marang dodolan UTHR (United Therapeutics)|BMRN: Multiplikator Forward P/S|BridgeBio Pharma (BBIO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan bgm.ltd|COGT: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan xerispharma.com (XERS)|Multiplikator forward rega marang pendapatan Keros Therapeutics KROS|Multiplikator Forward P/S ARCT (arcturusrx.com)|Multiplikator Forward P/S Eton Pharmaceuticals, Inc. ETON|KMDA - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan FULC|MREO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Protalix BioTherapeutics, Inc. (PLX)|PLRX (Pliant Therapeutics, Inc.) - Multiplikator Forward P/S|Applied Therapeutics Inc. - Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Rein Therapeutics Inc (RNTX)|Rasio rega marang pendapatan sing dikarepake GELS|Aytu BioPharma, Inc. - Multiplikator forward rega marang pendapatan|Chemomab Therapeutics (CMMB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SRx Health - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Polyrizon Limited PLRZ|AEZS: Multiplikator Forward P/S|CYTH: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan INZY|RPHM: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan CSCI (COSCIENS Biopharma)